The association of low muscle mass with soluble receptor for advanced glycation end products (sRAGE): The Korean Sarcopenic Obesity Study (KSOS)

Diabetes Metab Res Rev. 2018 Mar;34(3). doi: 10.1002/dmrr.2974. Epub 2018 Jan 29.

Abstract

Background: Advanced glycation end products (AGEs) are accumulated with aging in various tissues of humans. The soluble receptor for AGEs (sRAGE) exerts a protective role against the development of aging-related chronic disorders by neutralizing the action of AGEs. We investigated the implication of sRAGE on low muscle mass in Asian men and women.

Methods: This cross-sectional study included a 390-participant, nondiabetic subcohort recruited within the framework of the Korean Sarcopenic Obesity Study, an ongoing prospective cohort study. Low muscle mass was defined based on the distribution of appendicular skeletal muscle mass divided by body mass index, as proposed by the Foundation for the National Institutes Sarcopenia Project.

Results: Serum sRAGE levels were significantly lower in participants with low muscle mass than in participants without low muscle mass (0.76 [0.60-1.00] ng/mL vs 0.87 [0.67-1.15] ng/mL, P = .005). In age- and sex-adjusted correlation analyses, appendicular skeletal muscle mass divided by body mass index was associated with sRAGE (r = 0.109, P = .037). Furthermore, decreased circulating levels of sRAGE are independently associated with low muscle mass (odds ratio = 0.254, P = .002) after adjusting for confounding factors, including insulin resistance and inflammatory markers.

Conclusions: The present study shows that a low circulating level of sRAGE may be an independent risk factor for the presence of low muscle mass.

Keywords: body composition; low muscle mass; sRAGE; sarcopenia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / metabolism*
  • Case-Control Studies
  • Cross-Sectional Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Obesity / complications*
  • Prognosis
  • Prospective Studies
  • Receptor for Advanced Glycation End Products / metabolism*
  • Sarcopenia / diagnosis*
  • Sarcopenia / etiology
  • Sarcopenia / metabolism

Substances

  • Biomarkers
  • Receptor for Advanced Glycation End Products
  • sRAGE protein, human